All News

A new retrospective study published in Obstetrics & Gynecology shows that robotics don’t improve benign hysterectomy outcomes and, in fact, increase cost of the surgery.

Clear, consistent steps for each specific surgical procedure should be adopted so that team members can become familiar with each procedure with repetition. Procedural steps for a robotic hysterectomy are shown in the video.

A plan for determining if intrauterine growth restriction is present, then monitoring and delivering when and how it's best for mother and infant.

A new registry-based study sheds light on patient factors that may influence risk of breast cancer associated with use of postmenopausal hormone replacement therapy (HRT)-including race, weight, and breast density. Findings from the report, published in The Journal of the National Cancer Institute, suggest the greatest association between HRT use and breast cancer in women with low/normal body mass index (BMI) and extremely dense breasts.

In an update of its 2002 recommendation on use of medications for breast cancer risk reduction, the U.S. Preventive Services Task Force (USPSTF) is encouraging informed decision-making and cautioning against use of medications for prevention in women who are not at increased risk of the disease.

For many physicians, no matter their specialty, the one thing that keeps them up at night is fear of medical malpractice lawsuits. Elisabeth Madden, partner at Lynch Gilardi and Grummer law firm in San Francisco, is an attorney with more than 20 years’ experience defending healthcare providers. In this article, based on a session at a recent conference for dermatologic surgeons, Ms. Madden explains some of the top ways surgeons can avoid medical malpractice lawsuits.

The Food and Drug Administration’s (FDA) advisory committee cleared the way for the approval of pertuzumab (Perjeta) to treat patients before they have surgery to remove their HER2-positive tumors. If approved, pertuzumab would be the first neoadjuvant drug approval for any form of cancer. The drug was already approved by the FDA for treatment of late-stage breast cancer last year.

The US Food and Drug Administration approved the new drug application (NDA) for Merck’s investigational fertility treatment corifollitropin alfa. Merck is seeking approval for the use of corifollitropin alfa in controlled ovarian stimulation (COS). If approved, the drug would be the first sustained follicular stimulant available in the United States.